The free event will discuss key insights into achieving impactful patient partnerships and advocacy

The approval broadens the drug’s label to include fifth treatment option in the relapsed/refractory multiple myeloma setting

The move will expand Janssen’s presence in autoimmune diseases

Trusts should aim to recruit at least 60% of eligible COVID-19 patients into trials

The treatment, developed by UCL clinicians, allows for surgery and radiation therapy at the same time

Updated Date: Thu, 13 Aug 2020 00:00:00 EDT

Novartis gets a green light to challenge Roche, Sanofi with delayed MS med Kesimpta chelfand Thu, 08/20/2020 – […]

The government has announced that it will lift the cap on the number of medical school places in […]

Eli Lilly, Pfizer, Merck among Big Pharma losers in China’s latest round of procurement bidding esagonowsky Thu, 08/20/2020 […]

Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus aliu Thu, 08/20/2020 – 10:11